Patients with a HER2-positive breast cancer show the highest OS rates (median OS of 11.6 months, 95% CI: 10.0–13.4) in the evaluation of the BMBC Registry, and the lowest survival rates could be shown for patients with triple-negative breast cancer (4.6 months, 95% CI: 3.9–5.4). Here, ERBB2 is linked to breast carcinoma.